Dierig, A., Hoelscher, M., Schultz, S., Hoffmann, L., Jarchow-MacDonald, A., Svensson, E., . . . Heinrich, N. (2023). A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Current controlled trials in cardiovascular medicine, 24(1), 382-15. https://doi.org/10.1186/s13063-023-07354-5
Chicago-Zitierstil (17. Ausg.)Dierig, A., et al. "A Phase IIb, Open-label, Randomized Controlled Dose Ranging Multi-centre Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-response Relationship of Different Doses of Delpazolid in Combination with Bedaquiline Delamanid Moxifloxacin in Adult Subjects with Newly Diagnosed, Uncomplicated, Smear-positive, Drug-sensitive Pulmonary Tuberculosis." Current Controlled Trials in Cardiovascular Medicine 24, no. 1 (2023): 382-15. https://doi.org/10.1186/s13063-023-07354-5.
MLA-Zitierstil (9. Ausg.)Dierig, A., et al. "A Phase IIb, Open-label, Randomized Controlled Dose Ranging Multi-centre Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Exposure-response Relationship of Different Doses of Delpazolid in Combination with Bedaquiline Delamanid Moxifloxacin in Adult Subjects with Newly Diagnosed, Uncomplicated, Smear-positive, Drug-sensitive Pulmonary Tuberculosis." Current Controlled Trials in Cardiovascular Medicine, vol. 24, no. 1, 2023, pp. 382-15, https://doi.org/10.1186/s13063-023-07354-5.